A Framework for Clinical Trials of Neurobiological Interventions That Target the Gut-Brain Axis in Inflammatory Bowel Disease
The DOI matches its Crossref record; 78 of the 87 references it cites were found in a registry or an index.
Abstract
A growing body of evidence from preclinical, translational, and clinical studies supports a bidirectional relationship within the gut-brain axis that contributes to neurobiological symptoms including anxiety, depression, fatigue, stress, and sleep disturbance. These symptoms have a significant impact on health-related quality of life and functional ability in individuals with inflammatory bowel disease. Clinical studies that generate high-quality evidence on pharmacological and nonpharmacological (eg, psychosocial, behavioral) interventions are needed to ultimately improve access to safe and effective therapies that have a meaningful impact on patients and to guide medical and regulatory decisions. This review outlines a framework for designing and conducting randomized controlled trials for interventions that target neurobiological symptoms in patients with inflammatory bowel disease based on the most recent guidance published within the past 5 years from policy makers, clinicians specialized in inflammatory bowel disease, patient-reported outcomes methodologists, health economists, patient advocates, industry representatives, ethicists, and clinical trial experts. © 2021 Crohn's & Colitis Foundation. Published by Oxford University Press. All rights reserved.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234
A Global Measure of Perceived Stress
Cohen, S., Kamarck, T., & Mermelstein, R. (1983) · Journal of Health and Social Behavior · doi:10.2307/2136404 · Cited by 32,807
A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.10.1092 · Cited by 31,765
A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale
Johns, M. W. (1991) · Sleep · doi:10.1093/sleep/14.6.540 · Cited by 17,364
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883
Jaeschke, R., Singer, J., & Guyatt, G. H. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90005-6 · Cited by 4,982
Unravelling the pathogenesis of inflammatory bowel disease
Xavier, R. J., & Podolsky, D. K. (2007) · Nature · doi:10.1038/nature06005 · Cited by 4,364
Smets, E. M. A., Garssen, B., Bonke, B., & De Haes, J. C. J. M. (1995) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(94)00125-o · Cited by 3,613
Research works printed but not linked: 17
- U.S. Food & Drug Administration., 2021, Code of Federal Regulations Title 21
- U.S. Food & Drug Administration., 2019, E8(R1) General considerations for clinical studies
- U.S. Food & Drug Administration., 2016, BEST (Biomarkers, EndpointS, and other Tools) Resource.
- European, 1998, ICH E8 General considerations for clinical trials
- U.S. Food & Drug Administration., DDT COA #000015: PROMIS® Short Form Fatigue 10a in Rheumatoid Arthritis
- U.S. Food & Drug Administration., 2017, Multiple endpoints in clinical trials guidance for industry.
- U.S. Food & Drug Administration., 2018, methods to identify what is important to patients and select, develop or modify fit-for-purpose clinical outcomes assessments
- U.S. Food & Drug Administration., 2019, incorporating clinical outcome assessments into endpoints for regulatory decision making
- U.S., 2020, Principles for selecting, developing, modifying, and adapting patient-reported outcome instruments for use in medical device evaluation
- U.S. Food & Drug Administration., 2018, Patient-focused drug development: collecting comprehensive and representative input
- Campbell, 2013, FDA guidance: design considerations for pivotal clinical investigations for medical devices
- Canadian Agency for Drugs and Technologies in Health., 2016, Entyvio (vedolizumab). Appendix 5: validity of outcome measures
- HealthMeasures., 2021, PROMIS® Score Cut Points
- Slagle, 2015, A Regulatory Perspective on Disease-Specific Outcome Measures: How does PROMIS Fit?
- Cohen, 1988, Perceived stress in a probability sample of the United States. In: Spacapan S, Oskamp S, eds, The social psychology of health. Sage Publications, Inc.;, 31
- Spielberger, 1989, State-Trait Anxiety Inventory: A Comprehensive Bibliography.
- Beck, 1996, Manual for the Beck Depression Inventory–II., San Antonio, TX: Psychological Corporation
Cited by
Jha, M., Waheed, A., Hooti, J. A., Nair, S., Najam, A., Mal, M. M., Tummala, N., Shariq, A. S., Hurairah, A., & Daniel, M. G. (2025) · Health Science Reports · doi:10.1002/hsr2.71157 · Cited by 11
Su, X.-Y., Wang, Y.-N., Huang, Y., & Dai, C. (2025) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2025.11305/2025 · Cited by 3
Stoikevych, M. V., Nedzvetskaya, N. V., & Tarasova, T. S. (2026) · GASTROENTEROLOGY · doi:10.22141/2308-2097.60.3.2026.736
Metadata
- Authors
- Tse, C. S., Singh, S., & Sandborn, W. J.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Sandborn, William J
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-07-09
- Volume
- 28
- Issue
- 5
- Pages
- 788-800
- ISSN
- 1078-0998 (ISSN-L)
- 1536-4844
- OpenAlex
- W3181381795
- Semantic Scholar
- 2da748fc1e0c134dc49f928c4fc57f77dd474080
- Cited by
- 3
- References
- 87
- Citations by year
- 2026: 1 · 2025: 2
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Inflammatory Bowel Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
- Keywords
- gut-brain axis, inflammatory bowel disease
- MeSH terms
- Brain-Gut Axis, Anxiety, Chronic Disease, Depression, Humans, Quality of Life, Sleep Wake Disorders, Inflammatory Bowel Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Framework for Clinical Trials of Neurobiological Interventions That Target the Gut-Brain Axis in Inflammatory Bowel Disease. https://app.cochat.ai/papers/10.1093/ibd/izab153
- The paper
- Tse, C. S., Singh, S., & Sandborn, W. J. (2022). A Framework for Clinical Trials of Neurobiological Interventions That Target the Gut-Brain Axis in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izab153
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.